Autopsy report · NCT04105985

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics

“Manufacturer discontinued drug before any participants could be enrolled.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Virginia Commonwealth University

Sponsor type

University, hospital or other

Conditions

Caries,Dental; Apical Periodontitis

Interventions

Kovanaze Nasal Spray; Articaine Injection

Participants

0

Trials that died the same way

• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
  “This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.” (70% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (70% match in meaning)
• A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
  “Study drug dosing was permanently discontinued at the Sponsor's discretion based on frequency and nature of skin and subcutaneous tissue disorders.” (70% match in meaning)
• One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
  “The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.” (68% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.